Ascendis Pharma (ASND) Tops Q2 EPS by 45c

Ascendis Pharma (NASDAQ: ASND) reported Q2 EPS of (EUR0.82), EUR0.45 better than the analyst estimate of (EUR1.27). Revenue for the quarter came in at EUR158.05 million versus the consensus estimate of EUR142.38 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• ACI Worldwide exploring sale of billing division - Reuters
• Boeing to resume issuing 737 MAX and 787 airworthiness certificates next week
• 3Knights Dynamics Group files for Nasdaq IPO at $4-$5 per share